Brief: Anixa Biosciences And Cleveland Clinic Present Positive Data For Phase 1 Study Of Breast Cancer Vaccine
17/04/2023 19:39
Anixa Biosciences Inc ANIX.O :
* ANIXA BIOSCIENCES AND CLEVELAND CLINIC PRESENT POSITIVE
DATA FOR
PHASE 1 STUDY OF BREAST CANCER VACCINE
* ANIXA BIOSCIENCES INC - IMMUNE RESPONSES WERE OBSERVED AT
ALL
DOSE LEVELS
* ANIXA BIOSCIENCES INC - TRIAL IS FUNDED BY A GRANT FROM
U.S.
DEPARTMENT OF DEFENSE TO CLEVELAND CLINIC
Source text for Eikon: ID:nPn52DCjca
Further company coverage: ANIX.O
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine